Enliven Therapeutics Inc (ELVN)

$60.07 +0.53 (0.90%)
Market Cap 4.36B
Revenue (ttm) 0.00
Net Income (ttm) -103.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 619,300
Avg Vol 1,566,522
Day's Range N/A - N/A
Shares Out 73.27M
Stochastic %K 65%
Beta 0.27
Analysts Strong Sell
Price Target $70.90

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 720 647 8519
Address:
6200 Lookout Road, Boulder, United States
anachartanalyst
anachartanalyst Aug. 18 at 12:01 PM
$ELVN https://anachart.com/wp-content/uploads/2026/08/1787054473_soc-img.jpg
0 · Reply
Quantumup
Quantumup Aug. 18 at 11:15 AM
Barclays🏁Enliven Therapeutics: Overweight-$78 $NVS TERN - $MRK William Blair🏁 $ELVN at Outperform Here's what Barclays and William Blair said in their initiation reports: https://x.com/Quantumup1/status/2089672206288626089?s=20
0 · Reply
thedentite
thedentite Aug. 17 at 8:11 PM
$ELVN That's a nice finish.
0 · Reply
TheRealiSwag
TheRealiSwag Aug. 17 at 5:44 PM
$KYTX is a hidden gem folks. There are many "under the radar" small cap bio's that warrant much more attention. KYTX is certainly one of them after a very strong quarterly update last week. Several strong catalyts on the docket next two months here. Buying most dips. $ELVN $CRVS $TERN have been others that have proved extremely successful. 🔥🔥🔥
0 · Reply
bluehorseshoe121
bluehorseshoe121 Aug. 4 at 7:44 PM
$ELVN how much is NVS buying $ELVN for???
3 · Reply
BobBobbertonnn
BobBobbertonnn Aug. 4 at 6:43 PM
$ELVN 🎯
0 · Reply
juhbubba
juhbubba Aug. 3 at 6:10 PM
$ELVN
0 · Reply
thedentite
thedentite Aug. 3 at 5:10 PM
$ELVN come on, no one is excited? This is the best stock I’ve ever owned.
0 · Reply
thedentite
thedentite Jul. 30 at 2:14 PM
$ELVN Does anyone have targets where they plan to sell shares? I hope there's a definitive answer to that...
1 · Reply
thedentite
thedentite Jul. 24 at 4:04 PM
$ELVN Yesss!
0 · Reply
Latest News on ELVN
Enliven price target raised to $73 from $62 at Mizuho

2026-08-18T11:06:38.000Z - 1 day ago

Enliven price target raised to $73 from $62 at Mizuho

Enliven initiated with an Outperform at William Blair

2026-08-18T10:15:49.000Z - 1 day ago

Enliven initiated with an Outperform at William Blair

Enliven initiated with an Overweight at Barclays

2026-08-18T09:15:08.000Z - 1 day ago

Enliven initiated with an Overweight at Barclays

Enliven price target raised to $75 from $60 at Baird

2026-08-06T13:26:56.000Z - 13 days ago

Enliven price target raised to $75 from $60 at Baird

Enliven price target raised to $82 from $80 at Stifel

2026-08-06T12:29:02.000Z - 13 days ago

Enliven price target raised to $82 from $80 at Stifel

Enliven price target lowered to $78 from $80 at Guggenheim

2026-08-06T10:46:26.000Z - 13 days ago

Enliven price target lowered to $78 from $80 at Guggenheim

Enliven price target raised to $80 from $67 at Goldman Sachs

2026-08-06T10:15:31.000Z - 13 days ago

Enliven price target raised to $80 from $67 at Goldman Sachs

Enliven price target raised to $68 from $55 at Clear Street

2026-08-06T10:11:40.000Z - 13 days ago

Enliven price target raised to $68 from $55 at Clear Street

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Aug 5, 2026, 4:05 PM EDT - 13 days ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 13 days ago

Enliven Therapeutics Quarterly report: Q2 2026

Enliven Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:00 PM EDT - 13 days ago

Enliven Therapeutics Earnings release: Q2 2026

Enliven price target raised to $67 from $59 at Goldman Sachs

2026-07-21T09:56:02.000Z - 4 weeks ago

Enliven price target raised to $67 from $59 at Goldman Sachs

Enliven price target raised to $65 from $56 at H.C. Wainwright

2026-07-09T10:10:44.000Z - 5 weeks ago

Enliven price target raised to $65 from $56 at H.C. Wainwright

Enliven price target raised to $80 from $60 at Stifel

2026-07-01T12:30:18.000Z - 7 weeks ago

Enliven price target raised to $80 from $60 at Stifel

Enliven price target raised to $70 from $45 at JonesResearch

2026-06-29T11:10:49.000Z - 7 weeks ago

Enliven price target raised to $70 from $45 at JonesResearch

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 15, 2026, 4:40 PM EDT - 2 months ago

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Why Is Enliven Therapeutics Stock (ELVN) Up Today?

2026-06-12T18:22:53.000Z - 2 months ago

Why Is Enliven Therapeutics Stock (ELVN) Up Today?

Enliven rises 9.9%

2026-06-12T16:08:54.000Z - 2 months ago

Enliven rises 9.9%

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Jun 11, 2026, 10:39 PM EDT - 2 months ago

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Enliven announces $250M common stock offering

2026-06-11T20:14:01.000Z - 2 months ago

Enliven announces $250M common stock offering

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 11, 2026, 4:05 PM EDT - 2 months ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven rises 14.8%

2026-06-11T14:08:06.000Z - 2 months ago

Enliven rises 14.8%

Enliven Therapeutics Transcript: Study update

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Enliven Therapeutics Transcript: Study update

Enliven Therapeutics Press release: Study update

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Enliven Therapeutics Press release: Study update

Enliven Therapeutics Slides: Study update

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Enliven Therapeutics Slides: Study update

Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial

2026-06-11T12:17:12.000Z - 2 months ago

Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 2 months ago

Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Jun 3, 2026, 4:05 PM EDT - 2 months ago

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Enliven Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 27, 2026, 2:30 PM EDT - 2 months ago

Enliven Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Enliven Therapeutics to Present at Upcoming Investor Conferences

May 21, 2026, 4:05 PM EDT - 3 months ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

May 12, 2026, 9:53 AM EDT - 3 months ago

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

May 7, 2026, 4:05 PM EDT - 3 months ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Enliven Therapeutics Quarterly report: Q1 2026

Enliven Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Enliven Therapeutics Earnings release: Q1 2026

Enliven Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Enliven Therapeutics Proxy statement: Proxy filing

Enliven Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Enliven Therapeutics Proxy statement: Proxy filing

Enliven Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Enliven Therapeutics Proxy statement: Proxy filing

Enliven Therapeutics Annual report: Q4 2025

Mar 3, 2026, 3:00 PM EST - 6 months ago

Enliven Therapeutics Annual report: Q4 2025

Enliven Therapeutics Earnings release: Q4 2025

Mar 3, 2026, 3:00 PM EST - 6 months ago

Enliven Therapeutics Earnings release: Q4 2025

Enliven Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 10:30 AM EST - 6 months ago

Enliven Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 6 months ago

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Jan 8, 2026, 9:00 AM EST - 7 months ago

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Jan 7, 2026, 9:00 AM EST - 8 months ago

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Dec 11, 2025, 4:21 PM EST - 8 months ago

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Dec 11, 2025, 9:00 AM EST - 8 months ago

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 11:00 AM EST - 9 months ago

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Nov 12, 2025, 4:05 PM EST - 9 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Enliven Therapeutics Earnings release: Q3 2025

Enliven Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Enliven Therapeutics Quarterly report: Q3 2025

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Aug 25, 2025, 6:20 PM EDT - 1 year ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Enliven Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Quarterly report: Q2 2025

Enliven Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q2 2025

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 16, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Transcript: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Transcript: Study Update

Enliven Therapeutics Press release: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Press release: Study Update

Enliven Therapeutics Slides: Study Update

Jun 13, 2025, 1:30 PM EDT - 1 year ago

Enliven Therapeutics Slides: Study Update

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 9:30 AM EDT - 1 year ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Jun 13, 2025, 6:02 AM EDT - 1 year ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Enliven Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Enliven Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 27, 2025, 1:00 PM EDT - 1 year ago

Enliven Therapeutics Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Enliven Therapeutics Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Quarterly report: Q1 2025

Enliven Therapeutics Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q1 2025

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

May 14, 2025, 9:56 AM EDT - 1 year ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Apr 2, 2025, 4:03 PM EDT - 1 year ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Final Trade: CVX, XLE, ELVN, COF

Mar 21, 2025, 6:38 PM EDT - 1 year ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Enliven Therapeutics Annual report: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Enliven Therapeutics Annual report: Q4 2024

Enliven Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Enliven Therapeutics Earnings release: Q4 2024

Enliven Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 10:30 AM EST - 1 year ago

Enliven Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 4:30 AM EST - 1 year ago

Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Enliven Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Enliven Therapeutics Quarterly report: Q3 2024

Enliven Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Enliven Therapeutics Earnings release: Q3 2024

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Why Enliven is this analyst's top biotech stock pick

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 28, 2024, 9:35 AM EDT - 2 years ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Sep 18, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

Enliven Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Enliven Therapeutics Quarterly report: Q2 2024

Enliven Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q2 2024

Enliven Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 3:20 PM EDT - 2 years ago

Enliven Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Enliven Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

May 29, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Enliven Therapeutics Quarterly report: Q1 2024

Enliven Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q1 2024

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Registration statement: Registration Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Registration statement: Registration Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Transcript: Study Update

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Transcript: Study Update

Enliven Therapeutics Slides: Study Update

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Enliven Therapeutics Slides: Study Update

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 11, 2024, 7:55 AM EDT - 2 years ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Apr 9, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Enliven Therapeutics Annual report: Q4 2023

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Enliven Therapeutics Annual report: Q4 2023

Enliven Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Enliven Therapeutics Earnings release: Q4 2023

Enliven Therapeutics Slides: Investor Presentation

Feb 29, 2024, 6:00 PM EST - 2 years ago

Enliven Therapeutics Slides: Investor Presentation

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 4:05 PM EST - 2 years ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Enliven Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 6:00 PM EST - 3 years ago

Enliven Therapeutics Quarterly report: Q3 2023

Enliven Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 6:00 PM EST - 3 years ago

Enliven Therapeutics Earnings release: Q3 2023

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 10, 2023, 4:05 PM EDT - 3 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Enliven Therapeutics Quarterly report: Q2 2023

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Quarterly report: Q2 2023

Enliven Therapeutics Earnings release: Q2 2023

Aug 9, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Earnings release: Q2 2023

Enliven Therapeutics Registration statement: Registration Filing

Jun 23, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Registration statement: Registration Filing

Enliven Therapeutics Quarterly report: Q1 2023

May 10, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Quarterly report: Q1 2023

Enliven Therapeutics Earnings release: Q1 2023

May 10, 2023, 6:00 PM EDT - 3 years ago

Enliven Therapeutics Earnings release: Q1 2023

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 23, 2023, 5:20 PM EST - 3 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven

Enliven Therapeutics Annual report: Q4 2022

Feb 10, 2023, 7:00 AM EST - 3 years ago

Enliven Therapeutics Annual report: Q4 2022

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Jan 25, 2023, 1:07 PM EST - 3 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Enliven Therapeutics Proxy statement: Proxy Filing

Oct 19, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Transcript: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 4 years ago

Enliven Therapeutics Transcript: M&A Announcement

Enliven Therapeutics Press release: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 4 years ago

Enliven Therapeutics Press release: M&A Announcement

Enliven Therapeutics Slides: M&A Announcement

Oct 13, 2022, 5:00 PM EDT - 4 years ago

Enliven Therapeutics Slides: M&A Announcement

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022, 4:35 PM EDT - 4 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Enliven Therapeutics Proxy statement: Proxy Filing

Oct 7, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Sep 23, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Sep 7, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Enliven Therapeutics Proxy statement: Proxy Filing

Apr 22, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Proxy statement: Proxy Filing

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Apr 5, 2022, 6:45 AM EDT - 4 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Enliven Therapeutics Annual report: Q4 2021

Mar 15, 2022, 8:00 AM EDT - 4 years ago

Enliven Therapeutics Annual report: Q4 2021

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Mar 8, 2022, 7:00 AM EST - 4 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Feb 10, 2022, 7:00 AM EST - 4 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 25, 2022, 7:00 AM EST - 4 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Jan 5, 2022, 7:00 AM EST - 5 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Dec 14, 2021, 7:00 AM EST - 5 years ago

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Nov 22, 2021, 7:00 AM EST - 5 years ago

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

anachartanalyst
anachartanalyst Aug. 18 at 12:01 PM
$ELVN https://anachart.com/wp-content/uploads/2026/08/1787054473_soc-img.jpg
0 · Reply
Quantumup
Quantumup Aug. 18 at 11:15 AM
Barclays🏁Enliven Therapeutics: Overweight-$78 $NVS TERN - $MRK William Blair🏁 $ELVN at Outperform Here's what Barclays and William Blair said in their initiation reports: https://x.com/Quantumup1/status/2089672206288626089?s=20
0 · Reply
thedentite
thedentite Aug. 17 at 8:11 PM
$ELVN That's a nice finish.
0 · Reply
TheRealiSwag
TheRealiSwag Aug. 17 at 5:44 PM
$KYTX is a hidden gem folks. There are many "under the radar" small cap bio's that warrant much more attention. KYTX is certainly one of them after a very strong quarterly update last week. Several strong catalyts on the docket next two months here. Buying most dips. $ELVN $CRVS $TERN have been others that have proved extremely successful. 🔥🔥🔥
0 · Reply
bluehorseshoe121
bluehorseshoe121 Aug. 4 at 7:44 PM
$ELVN how much is NVS buying $ELVN for???
3 · Reply
BobBobbertonnn
BobBobbertonnn Aug. 4 at 6:43 PM
$ELVN 🎯
0 · Reply
juhbubba
juhbubba Aug. 3 at 6:10 PM
$ELVN
0 · Reply
thedentite
thedentite Aug. 3 at 5:10 PM
$ELVN come on, no one is excited? This is the best stock I’ve ever owned.
0 · Reply
thedentite
thedentite Jul. 30 at 2:14 PM
$ELVN Does anyone have targets where they plan to sell shares? I hope there's a definitive answer to that...
1 · Reply
thedentite
thedentite Jul. 24 at 4:04 PM
$ELVN Yesss!
0 · Reply
thedentite
thedentite Jul. 21 at 5:49 PM
$ELVN Great day!
0 · Reply
thedentite
thedentite Jul. 15 at 2:56 PM
$ELVN Run little buddy, run!
0 · Reply
kxhonda
kxhonda Jul. 11 at 12:35 AM
$ELVN let’s goo!!!
0 · Reply
IN0V8
IN0V8 Jul. 9 at 5:41 PM
$ELVN Buying Opportunity H.C. Wainwright raises target price to $64 from $56
0 · Reply
thedentite
thedentite Jul. 8 at 3:57 PM
$ELVN Healthy pullback here before the next leg up. Added.
0 · Reply
Egerton
Egerton Jul. 8 at 3:50 PM
$ELVN Why down 4.5%? $XBI is only down 2.5% and $IBB onky 1.8%. Haven’t seen any news.
0 · Reply
thedentite
thedentite Jul. 7 at 4:43 PM
$ELVN Woohooo let's do this.
0 · Reply
thedentite
thedentite Jul. 1 at 3:08 PM
$ELVN There's my dip! Now up to 2000 shares.
0 · Reply
thedentite
thedentite Jun. 29 at 2:11 PM
$ELVN I really hope for a big dip down to 46-47 to pick back up a few more shares.
0 · Reply
mhoward1711
mhoward1711 Jun. 26 at 11:53 AM
$ELVN she just can’t keep that 50
1 · Reply
thedentite
thedentite Jun. 23 at 4:20 PM
$ELVN Yet another amazing day!
0 · Reply
thedentite
thedentite Jun. 22 at 2:52 PM
$ELVN Why is sentiment bearish on this stock? Who can possibly be bearish?
0 · Reply